摘要
目的比较利培酮联合米氮平或帕罗西汀治疗精神分裂症阴性症状的临床效果。方法 84例精神分裂症阴性症状患者随机分为实验组和对照组,对照组采用利培酮治疗,实验组则采用利培酮联合米氮平或帕罗西汀治疗,比较两组患者的临床效果。结果实验组PANSS(阳性与阴性症状量表)评分低于对照组,治疗总有效率高于对照组(P<0.01);两组患者治疗时出现的症状量表(TESS)评分差异无统计学意义(P>0.05)。结论利培酮联合米氮平或帕罗西汀治疗精神分裂症阴性症状患者,安全有效。
Objective To compare the clinical efficacy of risperidone combined with mirtazapine or paroxetine in the treatment of negative symptoms of schizophrenia. Methods 84 patients with schizophreniawere randomly divided into experimental group and control group. The control group was treated with risperidone, while the experimental group was treated with risperidone combined with mirtazapine or paroxetine. To compare the clinical effect of the two groups. Results The experimental group PANSS （positive and negative symptom scale） score was lower than the control group, the total efficiency of treatment was higher than the control group （P 〈 0.01）. The symptoms scale of two groups of patients during treatment （TESS） score had no significant difference （P 〉 0.05）. Conclusion Risperidone combined with mirtazapine or paroxetine is safe and effective in the treatment of schizophrenia patients with negative symptoms.
出处
《中国卫生标准管理》
2017年第11期101-102,共2页
China Health Standard Management
